In vivo effects of recombinant interleukin-11 on myelopoiesis in mice

G. Hangoc, T. Yin, S. Cooper, P. Schendel, Chung Yang Yu Chung Yang, H. E. Broxmeyer

Research output: Contribution to journalArticle

73 Citations (Scopus)

Abstract

Purified recombinant human interleukin-11 (rhuIL-11) was assessed for its in vivo effects on the proliferation and differentiation of hematopoietic progenitors as well as its capacity to accelerate the recovery of a drug-suppressed hematopoietic system. Dosage and time sequence studies demonstrated that administration of IL-11 to normal mice resulted in increases in absolute numbers of femoral marrow and splenic myeloid (granulocyte-macrophage colony-forming unit [CFU-GM], burst-forming unit-erythroid [BFU-E], CFU-granulocyte, erythroid, macrophage, megakaryocyte) progenitor cells and in stimulation of these progenitors to a higher cell cycling rate. This was associated with increased numbers of circulating neutrophils. Administration of IL-11 to mice pretreated with cyclophosphamide decreased the time required to regain normal levels of neutrophil and platelet counts in peripheral blood. In addition, IL-11 accelerated reconstitution to normal range of myeloid progenitors from bone marrow and spleen of myelosuppressed mice. These data suggest that IL-11 may play an important role in the regulation of hematopoiesis, and the application of this novel cytokine may have clinical therapeutic benefits.

Original languageEnglish (US)
Pages (from-to)965-972
Number of pages8
JournalBlood
Volume81
Issue number4
StatePublished - Jan 1 1993

Fingerprint

Myelopoiesis
Interleukin-11
Granulocyte-Macrophage Progenitor Cells
Macrophages
Megakaryocyte-Erythroid Progenitor Cells
Neutrophils
Bone Marrow
Hematopoietic System
Erythroid Precursor Cells
Regain
Hematopoiesis
Platelets
Thigh
Platelet Count
Granulocytes
Cyclophosphamide
Bone
Reference Values
Blood
Spleen

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology

Cite this

Hangoc, G., Yin, T., Cooper, S., Schendel, P., Yu Chung Yang, C. Y., & Broxmeyer, H. E. (1993). In vivo effects of recombinant interleukin-11 on myelopoiesis in mice. Blood, 81(4), 965-972.

In vivo effects of recombinant interleukin-11 on myelopoiesis in mice. / Hangoc, G.; Yin, T.; Cooper, S.; Schendel, P.; Yu Chung Yang, Chung Yang; Broxmeyer, H. E.

In: Blood, Vol. 81, No. 4, 01.01.1993, p. 965-972.

Research output: Contribution to journalArticle

Hangoc, G, Yin, T, Cooper, S, Schendel, P, Yu Chung Yang, CY & Broxmeyer, HE 1993, 'In vivo effects of recombinant interleukin-11 on myelopoiesis in mice', Blood, vol. 81, no. 4, pp. 965-972.
Hangoc G, Yin T, Cooper S, Schendel P, Yu Chung Yang CY, Broxmeyer HE. In vivo effects of recombinant interleukin-11 on myelopoiesis in mice. Blood. 1993 Jan 1;81(4):965-972.
Hangoc, G. ; Yin, T. ; Cooper, S. ; Schendel, P. ; Yu Chung Yang, Chung Yang ; Broxmeyer, H. E. / In vivo effects of recombinant interleukin-11 on myelopoiesis in mice. In: Blood. 1993 ; Vol. 81, No. 4. pp. 965-972.
@article{50c9b05d98f04c6db35829ff737d1d42,
title = "In vivo effects of recombinant interleukin-11 on myelopoiesis in mice",
abstract = "Purified recombinant human interleukin-11 (rhuIL-11) was assessed for its in vivo effects on the proliferation and differentiation of hematopoietic progenitors as well as its capacity to accelerate the recovery of a drug-suppressed hematopoietic system. Dosage and time sequence studies demonstrated that administration of IL-11 to normal mice resulted in increases in absolute numbers of femoral marrow and splenic myeloid (granulocyte-macrophage colony-forming unit [CFU-GM], burst-forming unit-erythroid [BFU-E], CFU-granulocyte, erythroid, macrophage, megakaryocyte) progenitor cells and in stimulation of these progenitors to a higher cell cycling rate. This was associated with increased numbers of circulating neutrophils. Administration of IL-11 to mice pretreated with cyclophosphamide decreased the time required to regain normal levels of neutrophil and platelet counts in peripheral blood. In addition, IL-11 accelerated reconstitution to normal range of myeloid progenitors from bone marrow and spleen of myelosuppressed mice. These data suggest that IL-11 may play an important role in the regulation of hematopoiesis, and the application of this novel cytokine may have clinical therapeutic benefits.",
author = "G. Hangoc and T. Yin and S. Cooper and P. Schendel and {Yu Chung Yang}, {Chung Yang} and Broxmeyer, {H. E.}",
year = "1993",
month = "1",
day = "1",
language = "English (US)",
volume = "81",
pages = "965--972",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "4",

}

TY - JOUR

T1 - In vivo effects of recombinant interleukin-11 on myelopoiesis in mice

AU - Hangoc, G.

AU - Yin, T.

AU - Cooper, S.

AU - Schendel, P.

AU - Yu Chung Yang, Chung Yang

AU - Broxmeyer, H. E.

PY - 1993/1/1

Y1 - 1993/1/1

N2 - Purified recombinant human interleukin-11 (rhuIL-11) was assessed for its in vivo effects on the proliferation and differentiation of hematopoietic progenitors as well as its capacity to accelerate the recovery of a drug-suppressed hematopoietic system. Dosage and time sequence studies demonstrated that administration of IL-11 to normal mice resulted in increases in absolute numbers of femoral marrow and splenic myeloid (granulocyte-macrophage colony-forming unit [CFU-GM], burst-forming unit-erythroid [BFU-E], CFU-granulocyte, erythroid, macrophage, megakaryocyte) progenitor cells and in stimulation of these progenitors to a higher cell cycling rate. This was associated with increased numbers of circulating neutrophils. Administration of IL-11 to mice pretreated with cyclophosphamide decreased the time required to regain normal levels of neutrophil and platelet counts in peripheral blood. In addition, IL-11 accelerated reconstitution to normal range of myeloid progenitors from bone marrow and spleen of myelosuppressed mice. These data suggest that IL-11 may play an important role in the regulation of hematopoiesis, and the application of this novel cytokine may have clinical therapeutic benefits.

AB - Purified recombinant human interleukin-11 (rhuIL-11) was assessed for its in vivo effects on the proliferation and differentiation of hematopoietic progenitors as well as its capacity to accelerate the recovery of a drug-suppressed hematopoietic system. Dosage and time sequence studies demonstrated that administration of IL-11 to normal mice resulted in increases in absolute numbers of femoral marrow and splenic myeloid (granulocyte-macrophage colony-forming unit [CFU-GM], burst-forming unit-erythroid [BFU-E], CFU-granulocyte, erythroid, macrophage, megakaryocyte) progenitor cells and in stimulation of these progenitors to a higher cell cycling rate. This was associated with increased numbers of circulating neutrophils. Administration of IL-11 to mice pretreated with cyclophosphamide decreased the time required to regain normal levels of neutrophil and platelet counts in peripheral blood. In addition, IL-11 accelerated reconstitution to normal range of myeloid progenitors from bone marrow and spleen of myelosuppressed mice. These data suggest that IL-11 may play an important role in the regulation of hematopoiesis, and the application of this novel cytokine may have clinical therapeutic benefits.

UR - http://www.scopus.com/inward/record.url?scp=0027459101&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0027459101&partnerID=8YFLogxK

M3 - Article

C2 - 8428003

AN - SCOPUS:0027459101

VL - 81

SP - 965

EP - 972

JO - Blood

JF - Blood

SN - 0006-4971

IS - 4

ER -